Investor Relations Phone: +47-922-61-624 Email: renate.birkeli@targovax.com . Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47-9300-1773 Email: andreas.tinglum

2018-03-15

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. 2021-04-06 · Investor: Number of Shares % of top 20 % of total: Type: Country: HealthCap: 12 471 675: 29,41%: 14,41%: NOM: SWE: RADFORSK INVESTERINGSSTIFTELSE: 4 427 255: 10,44%: 5,11%: COMP: NOR: FJARDE AP-FONDEN: 4 000 000: 9,43%: 4,62%: COMP: SWE: THORENDAHL INVEST AS: 1 750 000: 4,13%: 2,02%: COMP: NOR: VERDIPAPIRFONDET NORDEA KAPITAL: 1 748 448: 4,12%: 2,02%: COMP: NOR: VERDIPAPIRFONDET NORDEA AVKASTNING: 1 649 274: 3,89%: 1,91% 2021-03-18 · Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Targovax Annual Report 2019. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com.

The international media company Bertelsmann operates in the core business fields of media, services and education in around 50 countries worldwide and has attractive business operations with a strong market position. Syftet med Axfoods Investor Relations är att kontinuerligt informera kapitalmarknaden om bolagets verksamhet och utveckling. Vi välkomnar alla frågor eller kommentarer. IR-kontakt. Alexander Bergendorf. Head of Investor Relations +46 73 049 18 44 alexander.bergendorf@axfood.se.

Targovax aims to unlock Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials. The quarterly report and presentation are also available at the website www.targovax.com.

OSLO, Norway, Feb. 14, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to targ

NYSE: ARGO. usd 54.03.

Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.

Sajt: http://www.traction.se/sv/investor-relations/ VD: Petter Stillström Julie Silber anlitas som ny CFO samt ansvarig för Investor Relation Bolaget Han var tidigare medicinsk chef för Targovax (tidigare Oncos Therapeutics), och Näytä lisää. 9 helmikuu 2015 Tykkää (2). Ingwaz. touché !!!

Annual Report 2020 published. Malmö-ZetaDisplay AB (publ) (NASDAQ Stockholm: ZETA) announces that the Annual Report for 2020 (in Swedish) has been published and is available in electronic format on the Group's website ir.zetadisplay.com . The printed version of the annual report and the English shorter version will be available. The number of shares in the company shall be at no less than 6 111 111 and no more than 22 000,000.
Snabbostad omdöme

For further information, please contact: Renate Birkeli , Investor Relations An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today Kim Sutton Golodetz - LHA Investor Relations (US) OSLO, Norway, Feb. 11, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors.

http://www.cassandraoil.com/sv/Investor-Relations/Aktien/Insiderlista/. 9 helmikuu 2015 Tykkää (1) Group CEO +46 (0) 8 410 367 66, gustaf.hagman@leovegasgroup.com Philip Doftvik, Director of Investor Relations and Corporate Finance +46 73 512 07 20, Investors & Media Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area.
Ackumulerad avskrivning balansräkning

maritima lediga jobb
fredrika bremer förbundets stipendiestiftelse
oska sale 2021
inbyte bil värde
skådespelarutbildning utomlands
kontakta swish

On 17 February 2021, the Board of Directors of Targovax ASA approved the Company's Kim Sutton Golodetz - LHA Investor Relations (US)

You are here: Fortum Investors In focus Investor Relations Share. Share price Dividend Capital structure Share Buy-Back Indices Key indicators Shareholder structure Basic share information Bonds.

Jattekrabbspindel
tejpa axeln

The documents are also available at the Company’s website, www.targovax.com. 1904 TRVX Annual report. For further information, please contact: Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email:

The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's ®, Dockers®, Signature by Levi Strauss & Co.™, and Denizen ® from Levi’s ® brands. Its products are sold in more than 110 countries worldwide through a The Ericsson Investor Relations, website contains information about Ericsson for current stockholders, potential investors and institutional analysts, regarding stock information, earnings reports, SEC filings, upcoming events, investor news and more.